Overview
Sunshine is a diversified Sri Lankan group spanning healthcare, consumer products and agribusiness. The latest quarter showed a substantial acceleration in profit despite lower gross and operating margins, while the reported half-year result confirms that the improvement was not confined to the first quarter.
The market-wide valuation band is Fairly valued and the assessment remains neutral: stronger revenue and profit are offset by a demanding valuation against Sunshine's own record and a dividend payout that exceeds trailing earnings.
Price performance
At LKR 31.80 on 10 November 2026, SUN had gained 13.1% over one month, ahead of the ASPI's 9.2% gain over the same period. The share was 41.5% of the way through its 52-week range, rather than near either extreme.
Its record includes two falls of 15% or more in three years, with the deepest at 31% and not yet recovered. Trading has been quieter recently, and a LKR 1 million order is about 14% of what trades on a typical day, a noticeable part of a day's trading.
Valuation
At 20.5 times earnings, the price represents LKR 20.50 paid for every LKR 1 of trailing profit, versus a sector median of 13.6 times. The P/E sits at the 75th percentile of the diversified-holdings peer group, while the P/B of 3.1 means paying roughly LKR 3.10 for each LKR 1 of net assets and ranks at the 90th percentile.
The latest audited return on equity was 15.3%, which supports some premium to book value, but today's P/E is more expensive than at all 14 recorded year-ends. A buyer at this price is relying on the September quarter, which delivered 41.9% of trailing EPS; at its year-ago net margin, the same price would equate to 22.9 times earnings.
The 7.2% dividend yield is the sector's highest among peers with reported yields. Dividends rose from LKR 0.287 in FY2023 to LKR 1.80 in FY2026, but the trailing payout ratio is 148.4% and dividend cover is only 0.67 times, so the current distribution exceeds the profit it is measured against.
News and sentiment
Coverage has been unusually heavy, at 11 articles in the last 30 days against a normal monthly rate of 4.2. Of 17 material articles over 90 days, 11 were positive, three negative and three neutral, with the reporting dominated by results, the Zydus manufacturing venture and healthcare investments.
On 2 November, Sunshine reported first-half FY2027 revenue of LKR 40.2 billion, up 24.4%, and profit after tax of LKR 3.7 billion, up 44.3%. The reported figures cover the same half-year ending September as the latest filing, rather than a later period.
The Zydus joint venture is to invest more than US$20 million in a Horana pharmaceutical plant, with commercial operations reported as targeted for 2028. The disclosed terms do not state Sunshine's future revenue or profit contribution, so its earnings impact cannot yet be sized. Sunshine Healthcare also acquired a 21.92% interest in Doc990 for LKR 410.8 million.
Financials
September-quarter revenue rose 32.0% year-on-year to LKR 21.6 billion, while net profit increased 76.6% to LKR 2.3 billion. Operating profit grew more slowly, at 27.5%, so the larger net-profit gain was not solely an operating-margin story.
Gross margin was 29.1% versus 32.1% a year earlier, operating margin was 16.8% versus 17.4%, and net margin was 10.8% versus 8.1%. The gross margin was the worst of seven comparable September quarters, while operating margin was among the worst at six out of seven. However, September has been Sunshine's strongest quarter for operating margin on average over the six complete years on record, so the result should be judged against prior Septembers rather than weaker quarters in the year.
LKR 1.3 billion of operating profit was absorbed below the operating line by finance costs, tax, associates and other items. Equity rose to LKR 28.6 billion from LKR 27.3 billion a year earlier, while the share count was unchanged at 1.97 billion, so the year-on-year earnings comparison is not mechanically distorted by a share issue or subdivision.
Risks
The clearest financial risk is the gap between the dividend and trailing earnings: the payout ratio is 148.4% and dividend cover is 0.67 times. This does not establish a future dividend change, but it means the current yield rests on distributions larger than the trailing profit base.
At the March 2026 year-end, debt was 47.8% of equity attributable to owners and operating profit covered interest expense 12.94 times. The current ratio was 1.73 times, meaning short-term assets, including inventory and amounts owed by customers, exceeded bills due within a year. Cash conversion was 0.84 times, however, so not all operating profit arrived as operating cash during that year.
Minority shareholders received 39.4% of annual group profit, meaning group net profit is materially larger than the profit belonging to the ordinary shares being valued. Healthcare accounts for the largest reported segment exposure, and the company has reported regulated pharmaceutical price cuts as a margin pressure. Consumer and agribusiness operations also operate against an environment of elevated household-cost and fuel pressures, although the supplied backdrop does not establish their direct effect on Sunshine.
Outlook
As at 10 November 2026, the next scheduled catalyst is the interim filing for the quarter ending 31 December 2026, expected between 3 and 14 February 2027. It will update whether the reported half-year revenue and profit acceleration continued while regulated healthcare pricing and input costs remained in the background.
The LKR 0.50 first interim dividend went ex-date on 10 November 2026 and is due for payment on 30 November 2026; a buyer today does not receive it. The available data cannot yet quantify the earnings contribution from the Zydus plant or the Doc990 investment, leaving execution and eventual economics of those healthcare investments unresolved.